Sangamo BioSciences CEO To Present State Of The Industry Address At Alliance For Regenerative Medicine's Advanced Therapies Summit
RICHMOND, Calif., March 9, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that Edward Lanphier, Sangamo's president and CEO, will present an overview of the state of the Advanced Therapies Industry on Thursday, March 12, 2015 at the Alliance for Regenerative Medicine's (ARM) 5th Annual Advanced Therapies Summit, being held in Paris, France.
"Close international coordination is essential to advancing our field," said Edward Lanphier, Sangamo BioSciences president and CEO, and chairman of ARM. "This annual summit provides the opportunity to meet, collaborate with and learn from our global colleagues to forge closer ties to bring important medical advances to patients around the world."
Mr. Lanphier was elected to serve a two-year term as the Chairman of ARM beginning on January 1, 2015. Washington, DC-based ARM is an international organization that represents and supports industry, clinical institutions, patient advocates and other stakeholders in the development of safe and effective gene and cell therapies.
The Advanced Therapies Summit is a one-day meeting of top executives and clinical researchers from across Europe and the United States. The program will feature high-level, interactive talks with biotechnology and pharma leaders on the role their corporations play in advancing the field. Additionally, experts in translational medicine as well as regulatory and reimbursement thought-leaders will guide discussions focused on broadening the understanding of the advanced therapies sector, and the work needed to be done to continue its growth and success. For more information please visit http://www.alliancerm.org.
About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic CuresTM for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic gene regulation and genome editing. The Company has clinical stage programs to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728-T), beta-thalassemia (SB-BCLmR-HSPC), and NGF-AAV for Alzheimer's disease (CERE-110). Sangamo's other therapeutic programs are focused on monogenic and rare diseases. The Company has formed a strategic collaboration with Shire International GmbH to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and with Biogen Idec for hemoglobinopathies, such as sickle cell disease and beta-thalassemia. It has also established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO
SOURCE Sangamo BioSciences, Inc.
Share this article